Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Insitu Biologics Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and the distinct art units. This distribution indicates that each of the 3 pending actions is being processed in a different technical and personnel environment, which may lead to independent prosecution paths for each application.
CORNET, JEAN P is the busiest examiner for the portfolio. This examiner is managing 1 pending office action, while the other pending actions are handled by different examiners. With the 3 pending office actions divided among the distinct examiners, no single person has a concentrated influence over the portfolio's immediate results. Practitioners will need to manage separate relationships and navigate the specific requirements of the various art units to advance the company's goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615846 | SUSTAINED RELEASE CANCER THERAPEUTICS FORMULATIONS | OLSON, ANDREA STEFFEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17965738 | ECHOGENIC COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PAIN | HOERNER, PAUL ELLSWORTH | 240d overdue |
| 18631935 | SUSTAINED RELEASE STABLE EMULSION PHARMACEUTICAL FORMULATIONS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1693 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18631935 | SUSTAINED RELEASE STABLE EMULSION PHARMACEUTICAL FORMULATIONS | CORNET, JEAN P | 1628 | §103§112DP | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18615846 | SUSTAINED RELEASE CANCER THERAPEUTICS FORMULATIONS | OLSON, ANDREA STEFFEL | 1693 | §102§103 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 17965738 | ECHOGENIC COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PAIN | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | 240d overdue | Pending | Oct 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInsitu Biologics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Jean P Cornet has the most, with 1 of Insitu Biologics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
